<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00074412</url>
  </required_header>
  <id_info>
    <org_study_id>HPTN 046</org_study_id>
    <secondary_id>10142</secondary_id>
    <nct_id>NCT00074412</nct_id>
  </id_info>
  <brief_title>Using Nevirapine to Prevent Mother-to-Child HIV Transmission During Breastfeeding</brief_title>
  <official_title>A Phase III Trial to Determine the Efficacy and Safety of an Extended Regimen of Nevirapine in Infants Born to HIV-Infected Women to Prevent Vertical HIV Transmission During Breastfeeding</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      The many benefits of breastfeeding are well documented. However, because of the risk of
      mother-to-child transmission (MTCT) of HIV from an HIV infected mother to her infant, there
      is considerable concern over the practice, especially in developing countries. The purpose of
      this study is to determine the safety and effectiveness of the anti-HIV drug nevirapine (NVP)
      in preventing MTCT of HIV in breastfeeding infants born to HIV infected women in South
      Africa, Tanzania, Uganda, and Zimbabwe.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Breastfeeding provides general health, growth, and development benefits to an infant and
      significantly decreases the risk of certain acute and chronic diseases. Breastfeeding also
      decreases financial burden on the mother by decreasing the need for infant formula and health
      care for the infant. However, clinical evidence has shown that HIV can be readily transmitted
      through breast milk, although the risk of HIV MTCT over time while breastfeeding has been
      difficult to determine. Given the many advantages of breastfeeding and the significant
      obstacles to substituting formula for breast milk in developing countries, there is an urgent
      need to make breastfeeding by HIV infected women safe. This study will evaluate the safety
      and efficacy of an extended NVP regimen for prevention of MTCT of HIV through breastfeeding.

      This study will last approximately 3.5 years. Mother/infant pairs will be enrolled over a
      period of 18 to 24 months. During the third trimester of pregnancy, HIV infected participants
      will receive HIV counseling and the intrapartum/neonatal two-dose NVP prophylaxis regimen to
      prevent MTCT. Mothers will also be given infant feeding options counseling and information on
      administering the study drug to the infant. Infants who were randomly assigned to receive a
      placebo and older than 6 weeks of age as of 08/10/07 OR to receive NVP will continue their
      treatment assignment. Infants who were randomly assigned to receive a placebo and are 6 weeks
      of age or less as of 08/10/07 will receive open-label NVP through Day 42 of life. For all
      other participants, all randomized infants will receive extended NVP through 6 weeks (Day 42)
      of life. All eligible infants will be randomly assigned to one of two groups at Week 6
      following birth. The first group will receive extended NVP treatment; the second group will
      receive nevirapine placebo. Randomized infants will receive the extended NVP or NVP placebo
      through the first 6 months of life or until cessation of breastfeeding, whichever occurs
      earlier. Mothers will be instructed to begin giving their infants their assigned intervention
      starting at Day 3 to Day 7 postpartum. All mothers and infants outside of the study will be
      offered the local standard of care antiretroviral (ARV) regimen for the prevention of MTCT,
      but these ARVs will not be provided by the study.

      Follow-up evaluations will be conducted at Weeks 2 and 6 and Months 3, 6, 12, and 18 for
      mothers, and at Weeks 2, 5, 6, and 8 and Months 3, 4, 5, 6, 9, 12, and 18 for infants. Study
      visits will include physical examinations, blood tests (including HIV tests), and medical
      histories. Study participants will be followed for up to 3.5 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HIV Infection in Infants Determined to be HIV Uninfected at 6 Weeks Enrolled in Each Arm of the Study</measure>
    <time_frame>At Month 6</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency and Severity of Adverse Reactions Among Participating Infants</measure>
    <time_frame>6 weeks through 18 months</time_frame>
    <description>For those infants who were randomized at 6 weeks and who initiated study drug we looked at the frequency and severity of adverse reactions through 18 months of study. The severity of all AEs was graded according to the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events. The term severity is described as the intensity grade or level for specific event (i.e. mild, moderate, severe, or life-threatening). Severity is not the same as seriousness.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Infants Who Are Alive and HIV-uninfected in the Two Arms</measure>
    <time_frame>At Months 6 and 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative Rates of HIV Infection in the Two Arms</measure>
    <time_frame>At Month 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infant Survival Rates (Mortality Regardless of HIV Infection) in the Two Arms</measure>
    <time_frame>At Month 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and Duration of Maternal Plasma and Breast Milk NVP-resistant HIV Strains and the Relationship With HIV Transmission</measure>
    <time_frame>Throughout study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship Between Maternal Plasma and Breast Milk RNA Levels and the Risk of MTCT</measure>
    <time_frame>Throughout study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and Duration of NVP-resistant HIV Strains in Plasma of HIV-infected Infants</measure>
    <time_frame>Throughout study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of Disease Progression as Defined by CD4 Counts, HIV-1 RNA PCR, and Mortality in Infected Infants in the Two Arms</measure>
    <time_frame>Throughout study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NVP Concentrations in Infants Determined to be HIV-infected and in a Sample of HIV-uninfected Infants</measure>
    <time_frame>Week 8 and Month 3</time_frame>
    <description>Samples for NVP concentration were selected from the Version 3.0 infants who were randomized to NVP at 6 weeks and whose mothers were not on 3 or more antiretrovirals at the time of randomization. All infants HIV-infected by 6 months who met this criteria were selected and matched to HIV-uninfected infants who also met this criteria in a 1:3 ratio. NVP concentrations were measured by high liquid chromatographic/mass spectroscopy from the aforementioned infants plasma samples collected at week 8 and month 3. Median NVP concentrations were compared</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2026</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>2A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For infants: extended treatment with NVP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>For infants: extended treatment with NVP placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nevirapine</intervention_name>
    <description>10 mg/ml oral suspension taken once daily up to 6 months of age. Dosage will increase throughout study.</description>
    <arm_group_label>2A</arm_group_label>
    <other_name>NVP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nevirapine placebo</intervention_name>
    <description>Oral suspension taken once daily up to 6 months of age</description>
    <arm_group_label>2B</arm_group_label>
    <other_name>NVP placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Note: As of 08/10/07, the arm assignments for current and new participants have changed.
        Please see the above description for this trial for more information.

        Inclusion Criteria for Mothers:

          -  18 years of age or older

          -  HIV infected

          -  In third trimester of pregnancy, or at most 3 days post-delivery

          -  If baby is not yet born, planning to deliver at a facility where the study is being
             conducted

          -  Plan to breastfeed

        Exclusion Criteria for Mothers:

          -  Complications with this pregnancy

          -  Serious medical condition that would interfere with the study (e.g., that would
             prevent breastfeeding or adherence to the follow-up schedule), as judged by the
             on-site clinician

        Inclusion Criteria for Infants:

          -  Born to an HIV infected mother who is eligible for the study

          -  Weighed at least 2000 grams (4.4 lbs) at birth

          -  Blood sample obtained from the infant for HIV-1 DNA PCR, CBC with differential, and
             ALT

          -  Infants in a multiple birth are eligible only if both/all infants are eligible for the
             study and assigned to the same study group

          -  Able to breastfeed (e.g., mother and infant alive with no condition apparent that
             would prevent breastfeeding)

        Exclusion Criteria for Infants:

          -  HIV DNA PCR positive at birth

          -  ALT of Grade 2 or higher at birth

          -  Hemoglobin, absolute neutrophil count, or platelet count of Grade 3 or higher at birth

          -  Skin rash of Grade 2B (urticaria), Grade 3, or above

          -  Confirmed or suspected clinical hepatitis

          -  Serious illness or condition that would interfere with compliance with study
             procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hoosen M. Coovadia, MD, MBBS</last_name>
    <role>Study Chair</role>
    <affiliation>Centre for HIV Networking (HIVAN), Nelson Mandela School of Medicine, University of Natal</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laura Guay, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wafaie Fawzi, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Nutrition, Harvard School of Public Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yvonne Maldonado, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daya Moodley, MSc, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Obstetrics and Gynaecology, Nelson R Mandela School of Medicine, University of Natal</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CAPRISA Umlazi CRS</name>
      <address>
        <city>Umlazi</city>
        <state>KwaZulu-Natal</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Muhimbili University of Health and Allied Sciences (MUHAS) CRS</name>
      <address>
        <city>Dar es Salaam</city>
        <country>Tanzania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Makerere University- JHU Research Collaboration {MUJHU CARE LTD} CRS</name>
      <address>
        <city>Kampala</city>
        <state>Mpigi</state>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seke North CRS</name>
      <address>
        <city>Chitungwiza</city>
        <country>Zimbabwe</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Mary's CRS</name>
      <address>
        <city>Chitungwiza</city>
        <country>Zimbabwe</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
    <country>Tanzania</country>
    <country>Uganda</country>
    <country>Zimbabwe</country>
  </location_countries>
  <reference>
    <citation>Jackson JB, Musoke P, Fleming T, Guay LA, Bagenda D, Allen M, Nakabiito C, Sherman J, Bakaki P, Owor M, Ducar C, Deseyve M, Mwatha A, Emel L, Duefield C, Mirochnick M, Fowler MG, Mofenson L, Miotti P, Gigliotti M, Bray D, Mmiro F. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. Lancet. 2003 Sep 13;362(9387):859-68.</citation>
    <PMID>13678973</PMID>
  </reference>
  <reference>
    <citation>Mitchla Z, Sharland M. Current treatment options to prevent perinatal transmission of HIV. Expert Opin Pharmacother. 2000 Jan;1(2):239-48. Review.</citation>
    <PMID>11249545</PMID>
  </reference>
  <reference>
    <citation>Mofenson LM. Advances in the prevention of vertical transmission of human immunodeficiency virus. Semin Pediatr Infect Dis. 2003 Oct;14(4):295-308. Review.</citation>
    <PMID>14724794</PMID>
  </reference>
  <reference>
    <citation>Piwoz EG, Ross J, Humphrey J. Human immunodeficiency virus transmission during breastfeeding: knowledge, gaps, and challenges for the future. Adv Exp Med Biol. 2004;554:195-210. Review.</citation>
    <PMID>15384577</PMID>
  </reference>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 11, 2003</study_first_submitted>
  <study_first_submitted_qc>December 12, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2003</study_first_posted>
  <results_first_submitted>May 30, 2013</results_first_submitted>
  <results_first_submitted_qc>July 5, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 16, 2013</results_first_posted>
  <last_update_submitted>July 5, 2013</last_update_submitted>
  <last_update_submitted_qc>July 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 16, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV Seronegativity</keyword>
  <keyword>Treatment Experienced</keyword>
  <keyword>Treatment Naive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nevirapine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>HIV-infected pregnant women were recruited from antenatal clinics at DAIDS Clinical Trials Sites in Zimbabwe, South Africa, Uganda &amp; Tanzania between May 14, 2008 &amp; January 20th 2010. 1700 mother/infant pairs were enrolled &amp; infants were given daily doses of Nevirapine for 6 weeks at which point there were randomized to placebo or extended NVP.</recruitment_details>
      <pre_assignment_details>Infants were excluded from randomization if in first 42 days: had a positive HIV-1 DNA PCR, breastfeeding was discontinued, never initiated or permanently discontinued open-label NVP, certain graded abnormal labs, skin rash grade2B or higher, clinical hepatitis, serious illness/condition that prevented compliance, or use of rifampin/ketoconazole.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>For infants: extended treatment with NVP placebo</description>
        </group>
        <group group_id="P2">
          <title>Nevirapine</title>
          <description>For infants: extended treatment with NVP</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="763">Number of infants randomized at 6 weeks.</participants>
                <participants group_id="P2" count="759">Number of infants randomized at 6 weeks.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Week 8 Visit</title>
              <participants_list>
                <participants group_id="P1" count="759"/>
                <participants group_id="P2" count="759"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Month 3 Visit</title>
              <participants_list>
                <participants group_id="P1" count="759"/>
                <participants group_id="P2" count="755"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Month 4 Visit</title>
              <participants_list>
                <participants group_id="P1" count="758"/>
                <participants group_id="P2" count="752"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Month 5 Visit</title>
              <participants_list>
                <participants group_id="P1" count="756"/>
                <participants group_id="P2" count="750"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Month 6 Visit</title>
              <participants_list>
                <participants group_id="P1" count="748"/>
                <participants group_id="P2" count="748"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Month 9 Visit</title>
              <participants_list>
                <participants group_id="P1" count="741"/>
                <participants group_id="P2" count="741"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Month 12 Visit</title>
              <participants_list>
                <participants group_id="P1" count="733"/>
                <participants group_id="P2" count="735"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="681">Number of infants who completed final 18 month visit: out of 733 infants who were expected.</participants>
                <participants group_id="P2" count="675">Number of infants who completed final 18 month visit: out of 733 infants who were expected.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
                <participants group_id="P2" count="84"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="58"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Nevirapine</title>
          <description>For infants: extended treatment with NVP</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>For infants: extended treatment with NVP placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="759"/>
            <count group_id="B2" value="763"/>
            <count group_id="B3" value="1522"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="759"/>
                    <measurement group_id="B2" value="763"/>
                    <measurement group_id="B3" value="1522"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Ambiguous</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="363"/>
                    <measurement group_id="B2" value="398"/>
                    <measurement group_id="B3" value="761"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="395"/>
                    <measurement group_id="B2" value="365"/>
                    <measurement group_id="B3" value="760"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Tanzania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="98"/>
                    <measurement group_id="B2" value="99"/>
                    <measurement group_id="B3" value="197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uganda</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="259"/>
                    <measurement group_id="B2" value="261"/>
                    <measurement group_id="B3" value="520"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="171"/>
                    <measurement group_id="B2" value="171"/>
                    <measurement group_id="B3" value="342"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Zimbabwe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="231"/>
                    <measurement group_id="B2" value="232"/>
                    <measurement group_id="B3" value="463"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Categorical Infant Birthweight (g)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2000-2499</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2500-2999</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="214"/>
                    <measurement group_id="B2" value="211"/>
                    <measurement group_id="B3" value="425"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3000-3499</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="329"/>
                    <measurement group_id="B2" value="336"/>
                    <measurement group_id="B3" value="665"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=3500</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="166"/>
                    <measurement group_id="B2" value="163"/>
                    <measurement group_id="B3" value="329"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>HIV Infection in Infants Determined to be HIV Uninfected at 6 Weeks Enrolled in Each Arm of the Study</title>
        <time_frame>At Month 6</time_frame>
        <population>All infants who were randomly allocated to either treatment or placebo at 6 weeks of age under version 3.0 of the protocol were included in the analysis of the primary endpoint, HIV infection at 6 months. 127/1700 infants were enrolled but excluded from randomization at 6 weeks for various reasons as mentioned in the flow-through.</population>
        <group_list>
          <group group_id="O1">
            <title>Nevirapine</title>
            <description>For infants: extended treatment with NVP</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>For infants: extended treatment with NVP Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>HIV Infection in Infants Determined to be HIV Uninfected at 6 Weeks Enrolled in Each Arm of the Study</title>
          <population>All infants who were randomly allocated to either treatment or placebo at 6 weeks of age under version 3.0 of the protocol were included in the analysis of the primary endpoint, HIV infection at 6 months. 127/1700 infants were enrolled but excluded from randomization at 6 weeks for various reasons as mentioned in the flow-through.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="759"/>
                <count group_id="O2" value="763"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title># of HIV infections at 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" lower_limit="0.3" upper_limit="1.9"/>
                    <measurement group_id="O2" value="18" lower_limit="1.3" upper_limit="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title># of Infants at risk for HIV infection at 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="700"/>
                    <measurement group_id="O2" value="699"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>6 month Rate of Cum. HIV Infection (%)</param_type>
            <param_value>1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.3</ci_lower_limit>
            <ci_upper_limit>1.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>6 month Rate of Cum. HIV Infection (%)</param_type>
            <param_value>2.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.3</ci_lower_limit>
            <ci_upper_limit>3.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Assuming the cumulative HIV infection rate in placebo group would be 4.2% (2.6 at 6 wk. &amp; 6.7 at 6 mon.), we estimated 1500 mother/infant pairs would provide 90% power to detect a reduction in HIV infection from 4.2% to 1.4% at 6 mon. with a Pearson χ² test statistic and a one-sided false positive error rate of 0.025. Rate of cumulative infection was calculated using Kaplan-Meier method and rates between extended NVP group and placebo were done with the Z statistic.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.049</p_value>
            <p_value_desc>P-value has not been adjusted for interim analysis or multiple testing. A priori threshold for statistical significance was 0.05.</p_value_desc>
            <method>Z-test</method>
            <param_type>Z statistic</param_type>
            <param_value>1.973</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Frequency and Severity of Adverse Reactions Among Participating Infants</title>
        <description>For those infants who were randomized at 6 weeks and who initiated study drug we looked at the frequency and severity of adverse reactions through 18 months of study. The severity of all AEs was graded according to the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events. The term severity is described as the intensity grade or level for specific event (i.e. mild, moderate, severe, or life-threatening). Severity is not the same as seriousness.</description>
        <time_frame>6 weeks through 18 months</time_frame>
        <population>A total of 1519 infants, 758 in the NVP arm and 761 in the placebo arm, initiated study product and were thus included in the analysis for the frequency and severity of adverse reactions.</population>
        <group_list>
          <group group_id="O1">
            <title>Nevirapine</title>
            <description>For infants: extended treatment with NVP</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>For infants: extended treatment with NVP placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency and Severity of Adverse Reactions Among Participating Infants</title>
          <description>For those infants who were randomized at 6 weeks and who initiated study drug we looked at the frequency and severity of adverse reactions through 18 months of study. The severity of all AEs was graded according to the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events. The term severity is described as the intensity grade or level for specific event (i.e. mild, moderate, severe, or life-threatening). Severity is not the same as seriousness.</description>
          <population>A total of 1519 infants, 758 in the NVP arm and 761 in the placebo arm, initiated study product and were thus included in the analysis for the frequency and severity of adverse reactions.</population>
          <units>Number of Adverse Events</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="758"/>
                <count group_id="O2" value="761"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Adverse Events</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2014"/>
                <count group_id="O2" value="1964"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Life-Threatening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                    <measurement group_id="O2" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="375"/>
                    <measurement group_id="O2" value="332"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="694"/>
                    <measurement group_id="O2" value="677"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="832"/>
                    <measurement group_id="O2" value="838"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Infants Who Are Alive and HIV-uninfected in the Two Arms</title>
        <time_frame>At Months 6 and 18</time_frame>
        <population>There were 1522 infants randomized at 6 weeks of birth to either the extended Nevirapine arm (759) or the placebo arm (763).</population>
        <group_list>
          <group group_id="O1">
            <title>Nevirapine</title>
            <description>For infants: extended treatment with NVP</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>For infants: extended treatment with NVP placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Infants Who Are Alive and HIV-uninfected in the Two Arms</title>
          <population>There were 1522 infants randomized at 6 weeks of birth to either the extended Nevirapine arm (759) or the placebo arm (763).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="759"/>
                <count group_id="O2" value="763"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of Infants Alive and HIV-free at 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="689"/>
                    <measurement group_id="O2" value="683"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of Infants Alive and HIV-free at 18 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="629"/>
                    <measurement group_id="O2" value="616"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>The cumulative rate of HIV-free survival at 6 months in the extended NVP arm was calculated using the Kaplan-Meier method; while the 95% CI was calculated using Greenwood's formula.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Cum. Rate of HIV-free Survival 6mon (%)</param_type>
            <param_value>97.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>96.6</ci_lower_limit>
            <ci_upper_limit>98.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The cumulative rate of HIV-free survival at 6 months in the placebo arm was calculated using the Kaplan-Meier method; while the 95% CI was calculated using Greenwood's formula.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Cum. Rate of HIV-free Survival 6mon (%)</param_type>
            <param_value>96.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>95.5</ci_lower_limit>
            <ci_upper_limit>98.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The cumulative rates of HIV-free survival at 6 months were compared between the two groups using a Z-statistic.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.274</p_value>
            <p_value_desc>P-value was not adjusted for interim analysis or multiple testing.</p_value_desc>
            <method>Z-test</method>
            <param_type>Z statistic</param_type>
            <param_value>1.095</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>The cumulative rate of HIV-free survival at 18 months in the extended NVP arm was calculated using the Kaplan-Meier method; while 95% confidence intervals were calculated using Greenwood's formula.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Cum. Rate of HIV-free Survival 18mon (%)</param_type>
            <param_value>94.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>92.9</ci_lower_limit>
            <ci_upper_limit>96.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The cumulative rate of HIV-free survival at 18 months in the placebo arm was calculated using the Kaplan-Meier method; while the 95% confidence interval was calculated using Greenwood's formula.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Cum. Rate of HIV-free Survival 18mon (%)</param_type>
            <param_value>93.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>91.5</ci_lower_limit>
            <ci_upper_limit>95.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The cumulative rates of HIV-free survival at 18 months were compared between the two groups using a Z statistic.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.323</p_value>
            <p_value_desc>P-value was not adjusted for interim analysis or multiple testing.</p_value_desc>
            <method>Z-test</method>
            <param_type>Z statistic</param_type>
            <param_value>0.988</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relative Rates of HIV Infection in the Two Arms</title>
        <time_frame>At Month 18</time_frame>
        <population>A total of 1527 infants were randomized to either placebo or extended NVP. 5 of these infants were later found to be infected at the time of randomization (2 in NVP and 3 in Placebo). Thus, only 1522 infants were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Nevirapine</title>
            <description>For infants: extended treatment with NVP</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>For infants: extended treatment with NVP placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Relative Rates of HIV Infection in the Two Arms</title>
          <population>A total of 1527 infants were randomized to either placebo or extended NVP. 5 of these infants were later found to be infected at the time of randomization (2 in NVP and 3 in Placebo). Thus, only 1522 infants were included in the analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="759"/>
                <count group_id="O2" value="763"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title># of infants with HIV infection at 18 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title># of infants @ risk for HIV infection at 18 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="664"/>
                    <measurement group_id="O2" value="663"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>The cumulative rate of HIV infection at 18 months in the extended NVP arm was calculated using the Kaplan-Meier method; while the 95% confidence interval was calculated using Greenwood's formula.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>18 mon. Rate of Cum HIV Infection (%)</param_type>
            <param_value>2.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.1</ci_lower_limit>
            <ci_upper_limit>3.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The cumulative rate of HIV infection at 18 months in the placebo arm was calculated using the Kaplan-Meier method; while the 95% confidence interval was calculated using Greenwood's formula.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>18 mon. Rate of Cum. HIV Infection (%)</param_type>
            <param_value>3.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.9</ci_lower_limit>
            <ci_upper_limit>4.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The cumulative rates of HIV infection at 18 months were calculated using the Kaplan-Meier method and were compared between arms using a Z statistic.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.280</p_value>
            <p_value_desc>P-value was not adjusted for interim analysis or multiple testing.</p_value_desc>
            <method>Z-test</method>
            <param_type>Z statistic</param_type>
            <param_value>1.081</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Infant Survival Rates (Mortality Regardless of HIV Infection) in the Two Arms</title>
        <time_frame>At Month 18</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nevirapine</title>
            <description>For infants: extended treatment with NVP</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>For infants: extended treatment with NVP placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Infant Survival Rates (Mortality Regardless of HIV Infection) in the Two Arms</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="759"/>
                <count group_id="O2" value="763"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title># Infant Deaths at 18 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title># Infants at risk of death at 18 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="678"/>
                    <measurement group_id="O2" value="684"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Cumulative Mortality Rate at 18mon (%)</param_type>
            <param_value>4.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.0</ci_lower_limit>
            <ci_upper_limit>7.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Cumulative Mortality Rate at 18mon (%)</param_type>
            <param_value>4.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.7</ci_lower_limit>
            <ci_upper_limit>5.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The cumulative rates of mortality at 6 months, as calculated by Kaplan-Meier, were compared between the two groups using a Z-statistic.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.805</p_value>
            <p_value_desc>P-value was not adjusted for interim analysis or multiple testing</p_value_desc>
            <method>Z-test</method>
            <param_type>Z statistic</param_type>
            <param_value>-0.247</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Cumulative Mortality Rate at 6mon (%)</param_type>
            <param_value>1.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.4</ci_lower_limit>
            <ci_upper_limit>2.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Cumulative Mortality Rate at 6mon (%)</param_type>
            <param_value>1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.3</ci_lower_limit>
            <ci_upper_limit>1.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The cumulative mortality rates at 18 months, as calculated by Kaplan-Meier, were compared between the two groups using a Z statistic.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.719</p_value>
            <p_value_desc>P-value was not adjusted for interim analysis or multiple testing.</p_value_desc>
            <method>Z-test</method>
            <param_type>Z statistic</param_type>
            <param_value>-0.360</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>We compared the cumulative mortality rates, as calculated using Kaplan-Meier, between the two study groups over all 18 months of the study follow-up using a log-rank test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.611</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency and Duration of Maternal Plasma and Breast Milk NVP-resistant HIV Strains and the Relationship With HIV Transmission</title>
        <time_frame>Throughout study</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationship Between Maternal Plasma and Breast Milk RNA Levels and the Risk of MTCT</title>
        <time_frame>Throughout study</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency and Duration of NVP-resistant HIV Strains in Plasma of HIV-infected Infants</title>
        <time_frame>Throughout study</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rates of Disease Progression as Defined by CD4 Counts, HIV-1 RNA PCR, and Mortality in Infected Infants in the Two Arms</title>
        <time_frame>Throughout study</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>NVP Concentrations in Infants Determined to be HIV-infected and in a Sample of HIV-uninfected Infants</title>
        <description>Samples for NVP concentration were selected from the Version 3.0 infants who were randomized to NVP at 6 weeks and whose mothers were not on 3 or more antiretrovirals at the time of randomization. All infants HIV-infected by 6 months who met this criteria were selected and matched to HIV-uninfected infants who also met this criteria in a 1:3 ratio. NVP concentrations were measured by high liquid chromatographic/mass spectroscopy from the aforementioned infants plasma samples collected at week 8 and month 3. Median NVP concentrations were compared</description>
        <time_frame>Week 8 and Month 3</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Regardless of seriousness, severity or relatedness all AEs occurring in infants after enrollment (birth) and throughout the duration of the study (18 months) must be recorded.</time_frame>
      <desc>Non-serious adverse events occurring in an infant between randomization and 8 months of life will be collected on a case report form. Further, Serious AEs and AEs that meet the DAIDS expedited reporting criteria will be reported through case report forms throughout the entire 18 month follow-up period.</desc>
      <group_list>
        <group group_id="E1">
          <title>Nevirapine</title>
          <description>For infants: extended treatment with NVP</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>For infants: extended treatment with NVP placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (14.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="152" subjects_at_risk="758"/>
                <counts group_id="E2" subjects_affected="141" subjects_at_risk="761"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Aneamia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="761"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardipulmonary failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="761"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral palsy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="761"/>
              </event>
              <event>
                <sub_title>Congenital absence of bile ducts</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="761"/>
              </event>
              <event>
                <sub_title>Sickle cell anaemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="758"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="761"/>
              </event>
              <event>
                <sub_title>Sickle cell anaemia with crisis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="761"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blindness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="761"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="758"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="761"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="761"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="761"/>
              </event>
              <event>
                <sub_title>Intussusception</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="761"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="761"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="758"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="761"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="761"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="761"/>
              </event>
              <event>
                <sub_title>Sudden infant death syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="761"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="761"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="761"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="761"/>
              </event>
              <event>
                <sub_title>Abscess bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="761"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="761"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="761"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="758"/>
                <counts group_id="E2" events="7" subjects_affected="4" subjects_at_risk="761"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" events="19" subjects_affected="18" subjects_at_risk="758"/>
                <counts group_id="E2" events="23" subjects_affected="20" subjects_at_risk="761"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="761"/>
              </event>
              <event>
                <sub_title>Cerebral malaria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="761"/>
              </event>
              <event>
                <sub_title>Febrile infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="761"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="50" subjects_affected="45" subjects_at_risk="758"/>
                <counts group_id="E2" events="58" subjects_affected="50" subjects_at_risk="761"/>
              </event>
              <event>
                <sub_title>Gastroenteritis shigella</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="761"/>
              </event>
              <event>
                <sub_title>Giardiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="761"/>
              </event>
              <event>
                <sub_title>Injection site abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="761"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="758"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="761"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="758"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="761"/>
              </event>
              <event>
                <sub_title>Malaria</sub_title>
                <counts group_id="E1" events="50" subjects_affected="42" subjects_at_risk="758"/>
                <counts group_id="E2" events="40" subjects_affected="34" subjects_at_risk="761"/>
              </event>
              <event>
                <sub_title>Measles</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="758"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="761"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="758"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="761"/>
              </event>
              <event>
                <sub_title>Meningitis bacterial</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="758"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="761"/>
              </event>
              <event>
                <sub_title>Pericarditis tuberculous</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="761"/>
              </event>
              <event>
                <sub_title>Plasmodium falciparum infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="761"/>
              </event>
              <event>
                <sub_title>Pneumocystis jiroveci pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="761"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="21" subjects_affected="20" subjects_at_risk="758"/>
                <counts group_id="E2" events="29" subjects_affected="29" subjects_at_risk="761"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="758"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="761"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="758"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="761"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="758"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="761"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="758"/>
                <counts group_id="E2" events="12" subjects_affected="9" subjects_at_risk="761"/>
              </event>
              <event>
                <sub_title>Sepsis neonatal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="761"/>
              </event>
              <event>
                <sub_title>Tonsilitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="761"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="761"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="761"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Chemical poisoning</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="761"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="761"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="761"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="761"/>
              </event>
              <event>
                <sub_title>Traumatic shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="761"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="761"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="761"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="761"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="761"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="761"/>
              </event>
              <event>
                <sub_title>Kwashiorkor</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="758"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="761"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="761"/>
              </event>
              <event>
                <sub_title>Marasmus</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="758"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="761"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="758"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="761"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="761"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="761"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="758"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="761"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (14.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="614" subjects_at_risk="758"/>
                <counts group_id="E2" subjects_affected="618" subjects_at_risk="761"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="48" subjects_affected="42" subjects_at_risk="758"/>
                <counts group_id="E2" events="55" subjects_affected="51" subjects_at_risk="761"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="66" subjects_affected="62" subjects_at_risk="758"/>
                <counts group_id="E2" events="53" subjects_affected="43" subjects_at_risk="761"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="63" subjects_affected="57" subjects_at_risk="758"/>
                <counts group_id="E2" events="65" subjects_affected="55" subjects_at_risk="761"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis bacterial</sub_title>
                <counts group_id="E1" events="86" subjects_affected="76" subjects_at_risk="758"/>
                <counts group_id="E2" events="80" subjects_affected="72" subjects_at_risk="761"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="268" subjects_affected="188" subjects_at_risk="758"/>
                <counts group_id="E2" events="288" subjects_affected="208" subjects_at_risk="761"/>
              </event>
              <event>
                <sub_title>Malaria</sub_title>
                <counts group_id="E1" events="164" subjects_affected="122" subjects_at_risk="758"/>
                <counts group_id="E2" events="160" subjects_affected="112" subjects_at_risk="761"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" events="121" subjects_affected="97" subjects_at_risk="758"/>
                <counts group_id="E2" events="93" subjects_affected="79" subjects_at_risk="761"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" events="159" subjects_affected="135" subjects_at_risk="758"/>
                <counts group_id="E2" events="223" subjects_affected="187" subjects_at_risk="761"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="76" subjects_affected="73" subjects_at_risk="758"/>
                <counts group_id="E2" events="67" subjects_affected="64" subjects_at_risk="761"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="181" subjects_affected="145" subjects_at_risk="758"/>
                <counts group_id="E2" events="153" subjects_affected="121" subjects_at_risk="761"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <counts group_id="E1" events="60" subjects_affected="55" subjects_at_risk="758"/>
                <counts group_id="E2" events="44" subjects_affected="37" subjects_at_risk="761"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>In accordance with the Clinical Trial Agreement between NIAID (DAIDS) &amp; company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review &amp; comment. The publication or other disclosure can be delayed for up to thirty additional business days for manuscripts &amp; five business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The rate of maternal highly active antiretroviral therapy use was higher than expected in our study. Thus there were fewer infant infections which decreased the power to detect differences in HIV transmission risks between study groups.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Statistical Research Associate</name_or_title>
      <organization>Statistical Center for HIV/AIDS Research and Prevention</organization>
      <phone>2066677524</phone>
      <email>cherron@fhcrc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

